Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: www.pharmascience.com
Number of Employees: 1,500
Year Founded: 1983
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Pharmascience Inc. develops, manufactures, markets, and sells prescription, generic, over-the-counter (OTC), and behind-the-counter drug products. The company offers drugs for various therapeutic areas, including oncology, anti-infective, and cardiovascular; (Pr) pms-TRANDOLAPRIL, an angiotensin-converting enzyme inhibitor for the treatment of mild to moderate essential hypertension and the treatment following acute myocardial infarction; and (Pr)pms-PROGESTERONE, a progestin capsule for women with an intact uterus as an adjunct to postmenopausal estrogen replacement therapy to reduce the risk of endometrial hyperplasia and carcinoma. It also offers private label options for OTC drugs in various categories, such as pain management, cough and cold, stomach and gastro-intestinal ailments, and allergies to drug-store retail chains, grocery store banners, and distributors in Canada. In addition, the company offers services in the areas of medical equipment, advertising, and nursing services for pharmacists; and continuing education services. It serves pharmacists, drug wholesalers, retailers, and healthcare providers in Canada and internationally. The company was founded in 1983 and is based in Montreal, Canada with additional offices in Canada, Cyprus, Saudi Arabia, South Korea, Vietnam, and Ukraine. Pharmascience Inc. operates as a subsidiary of Joddes Limited.


Financial Information (Currency: CAD, in mm)
Total Revenue
 676.5
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 1,500
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Arès, Martin 
Chief Executive Officer
Goodman, Morris 
Co-Founder & Director
Goulet, Jean-Guy 
Chief Operating Officer

Key Board Members
Name
Title
Goodman, David W.
Chair of the Board
Goodman, Morris 
Co-Founder & Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
6111, Royalmount Avenue | Montreal, QC | H4P 2T4 | Canada
Phone: 514 340 9735   Fax: 514 340 9290

Parent Company
Joddes Limited


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Uman Pharma Inc.
As of November 13, 2014, Uman Pharma Inc. was acquired by Pharmascience Inc. Uman Pharma Inc. develops, manufactures, and markets generic anticancer drugs, specialty oncology products, and other injectable products. It develops and manufactures cytotoxic products, and high potent sterile injectable and solid dosage products for the oncology market. The company also provides contract manufacturing services for generic cytotoxic injectable drugs and oral solid dosage forms of non-cytotoxic drugs; and research and development services. In addition, it offers formulation and process development services, such as process development and optimization, development of analytical methods, validation of analytical methods, and validation of manufacturing process; and quality and compliance services, which include laboratories on site, chemistry and microbiological, stability testing programs, and CMC documents and CTD support. Further, the company provides commercial batches, including high potency sterile products, solid dosages (tablets and capsules), site transfer and validation process, lyophilization, and packaging and labeling. Furthermore, it offers pre-clinical and clinical batches, such as drug development, formulation, and scale-up; lyophilization cycles development; clinical manufacturing (Phase I to Phase IV); clinical trial sterile manufacturing and filling of vials and pre-filled syringes; clinical trial solid dosage manufacturing of tablets and capsules; placebos; release testing; and packaging and labeling of blinded and open label materials. The company distributes its products to hospitals, long-term care facilities, alternate care sites, and clinics in Canada. It also offers its products in Europe, the United States, and internationally. Uman Pharma Inc. has strategic partnerships with CFR Pharmaceuticals S. A. and Antares Pharma, Inc. The company was founded in 2008 and is based in Candiac, Canada.

United States and Canada
Biotechnology
-
-
-
Aegera Therapeutics Inc.
Aegera Therapeutics Inc. operates as a clinical-stage biotechnology company that develops therapeutics to address oncology and immuno-inflammation. The company focuses on developing HGS1029, a small molecule pan-IAP inhibitor for the treatment of a range of cancers; and AEG35156, a second generation antisense oligonucleotide that targets XIAP and is designed to lower the apoptotic threshold of cancer cells. It also focuses on various preclinical stage programs in the areas of oncology, autoimmune/inflammatory, solid tumors, fungal infections, and central nervous system diseases that include small molecule Bruton's tyrosine kinase inhibitors, inhibitor of apoptosis proteins, FMS inhibitors, and HSP90 inhibitors. Aegera Therapeutics Inc. was formerly known as Exogen Neurosciences, Inc. and changed its name to Aegera Therapeutics Inc. in May 2000. The company was founded in 1997 and is based in Montreal, Canada. As of May 26, 2011, Aegera Therapeutics Inc. operates as a subsidiary of Pharmascience Inc.

United States and Canada
Biotechnology
-
-
-
PendoPharm Inc.
PendoPharm Inc. develops, manufactures, licenses, and markets branded prescription medicines for health care professionals, pharmacists, and patients in Canada and internationally. It offers allergy, analgesics, cough, cold and sinus, gastroenterology, nasal care, and pediatrics products. It provides MYINFLA, a colchicine repurposed drug for the reduction of atherothrombotic events in adult patients. The company also offers specialty prescription products in therapeutic, such as gastroenterology, orthopedics, and urology. It sells its products through medical and retail sales representatives; wholesale and retail outlets, including pharmacy and mass grocery; affiliates; and distributors. PendoPharm Inc. was formerly known as Pangeo Pharma (Canada) Inc. and changed its name to PendoPharm Inc. in December 2004. The company was founded in 2003 and is based in Montreal, Canada. As of December 31, 2004, PendoPharm Inc. operates as a subsidiary of Pharmascience Inc.

United States and Canada
Pharmaceuticals
-
-
-
Edesa Biotech, Inc. (NasdaqCM:EDSA)
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that is in Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

United States and Canada
Biotechnology
-
9.00
0.00
Farmasains Ukraina Ink, Pidpryemstvo
Whol Drugs/Sundries

Europe
Health Care Distributors
11.00
-
-
Mistral Pharma Inc.
Mistral Pharma, Inc. operates as a development stage pharmaceutical product development and drug delivery company in Canada. It engages in the research and development of generic and branded drugs that incorporate oral controlled-delivery technologies. The company’s products consist of controlled-delivery branded products that contain an already approved drug or a combination of approved drugs, but that have a different release profile than already marketed products. Its product pipeline includes MIST-B01, a controlled-delivery formulation of a prescribed drug, which is approved for various treatments, including dermatology indications; MIST-B02, a controlled-delivery branded product in the gastroenterology field; and MIST-B03, a branded product in rheumatology. Mistral Pharma has licensing agreements with GlaxoSmithKline and Savit Consulting, Inc. The company is based in Dorval, Canada.

United States and Canada
Pharmaceuticals
0.00
3.00
1.00
Pharmaceutics International, Inc.
Pharmaceutics International, Inc. operates as a science-driven contract development and manufacturing company. It offers dosage form development and cGMP manufacturing services to biotech and specialty pharmaceutical industries. It manufactures a range of dosage forms, such as conventional tablets and capsules; controlled/delayed-release tablets and capsules; hard gelatin/HPMC liquid-filled capsules; soft gels; hot-melt extrusion; spray drying; powder for reconstitution; amorphous solid solutions; liquid formulations; inhalations (DPI, MDI, and nasal sprays); micronization/nanoparticle/microfluidization products; ointments/creams/gels; suspensions/syrups/solutions; sterile injectable products; freeze-dried products; and coated beads, tablets, and capsules. The company offers pre-formulation, formulation, clinical trial materials manufacturing, commercial manufacturing, clinical packaging and labeling, and clinical trial kit building and distribution services. Pharmaceutics International, Inc. was founded in 1994 and is based in Hunt Valley, Maryland.

United States and Canada
Life Sciences Tools and Services
36.00
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Nov-16-2017
Nov-16-2017
Private Placement
Buyer
RDD Pharma, Ltd.
Capital Point Ltd. (TASE:CPTP),OrbiMed Advisors LLC,Pharmascience Inc.

9.50
Sep-20-2017
Sep-20-2017
Private Placement
Buyer
Edesa Biotech, Inc. (NasdaqCM:EDSA)
Lumira Ventures,Pharmascience Inc.,Inveready Asset Management, S.G.E.I.C., S.A.

5.71
Aug-31-2016
Sep-06-2016
Private Placement
Buyer
Pharmaceutics International, Inc.
Signet Healthcare Partners,Athyrium Capital Management, LP,Hildred Capital Partners, LLC,Pharmascience Inc.,NB Alternatives Advisers LLC

93.00
Nov-13-2014
Nov-13-2014
Merger/Acquisition
Buyer
Uman Pharma Inc.
Pharmascience Inc.
CFR International SpA,UPGI Pharma Inc.
29.08
Apr-5-2012
May-25-2012
Private Placement
Buyer
BELLUS Health Inc.
Pharmascience Inc.

9.10
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-05-2023
Product-Related Announcements
Pharmascience Canada Launches New Generic Drug to Treat Hypertension
Jan-18-2023
Product-Related Announcements
Pharmascience Canada Launches (PR)pms-DEFERASIROX (TYPE J)
Jan-16-2023
Product-Related Announcements
Pharmascience Canada Launches Another Generic Drug with Multiple Indications
Nov-16-2022
Executive Changes - CEO
Pharmascience Inc. Announces the Appointment of Martin Arès as Chief Executive Officer, Effective January 3, 2023
Aug-29-2022
Product-Related Announcements
Lupin Limited in Partnership with Pharmascience Inc. Receives Tentative Approval from U.S. Fda for Dasatinib Tablets

Competitors
Acerus Pharmaceuticals Corporation, Apotex Inc., AstraZeneca Canada Inc., Bausch Health Companies Inc. (NYSE:BHC), Bayer Inc., Bristol Myers Squibb Canada Co., Cipher Pharmaceuticals Inc. (TSX:CPH), Endo International plc (OTCPK:ENDP.Q), GlaxoSmithKline Inc., HLS Therapeutics Inc. (TSX:HLS), Janssen Inc., Johnson & Johnson Inc., Merck Canada Inc., Merus Labs International Inc., Novartis Pharmaceuticals Canada Inc., Nuvo Pharmaceuticals Inc., PendoPharm Inc., Pfizer Canada Inc., Purdue Pharma Inc., Sandoz Canada Inc., Teva Canada Limited, Valeant Canada Ltd., Viatris Inc. (NasdaqGS:VTRS)

M&A Advisors
Davies Ward Phillips & Vineberg LLP


Advisors
M&A Advisors
Davies Ward Phillips & Vineberg LLP
Private Placement Advisors
Covington & Burling LLP, Davies Ward Phillips & Vineberg LLP, Sheppard, Mullin, Richter & Hampton LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 22, 2023 06:19 AM
Pharmascience Inc.
Pharmascience Inc
Reports
99
GlobalData

Aug 18, 2023 04:43 AM
Pharmascience Inc.
Pharmascience Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
47
GlobalData

Jun 16, 2023 02:55 AM
Pharmascience Inc.
Pharmascience Inc
Reports
101
GlobalData

May 17, 2023 06:28 AM
Pharmascience Inc.
Pharmascience Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
47
GlobalData

Mar 20, 2023 04:56 AM
Pharmascience Inc.
Pharmascience Inc
Reports
100
GlobalData

Feb 10, 2023 05:19 AM
Pharmascience Inc.
Pharmascience Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
47
GlobalData

Dec 13, 2022 03:10 AM
Pharmascience Inc.
Pharmascience Inc
Reports
105
GlobalData

Nov 10, 2022 04:56 AM
Pharmascience Inc.
Pharmascience Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
53
GlobalData

Sep 21, 2022 06:27 AM
Pharmascience Inc.
Pharmascience Inc
Reports
104
GlobalData

Aug 25, 2022 04:25 AM
Pharmascience Inc.
Pharmascience Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
53


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Paliperidone Palmitate Extended-Release Injectable Suspension Prefilled Syringes (Future), pms-FINGOLIMOD, Prpms-NITROFURANTOIN, Prpms-TRANDOLAPRIL


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Mar-04-2019
Pharmascience Inc.
ASX
MDC Executes HoA for NanaBis with Pharmascience Inc
654 KB

Key Board Members Details
Name
Title
Phone
Fax
Email
Goodman, David W.
Chair of the Board
514 340 9735
514 340 9290

Goodman, Morris 
Co-Founder & Director
514 340 9735
514 340 9290

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Arès, Martin 
Chief Executive Officer
514 340 9735
514 340 9290

Goodman, Morris 
Co-Founder & Director
514 340 9735
514 340 9290

Goulet, Jean-Guy 
Chief Operating Officer
514 340 9735
514 340 9290

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
